Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02825797 · ClinicalTrials.gov registry record · Phase 1
3BNC117 and 10-1074 in HIV-infected Individuals
A Phase 1 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02825797: Completed Phase 1 study, sponsored by Rockefeller University.
NCT02825797 is a Phase 1 study that has completed, run by Rockefeller University. The registered enrollment target is 34 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02825797, a Phase 1 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a phase 1b clinical trial to evaluate the safety, pharmacokinetics and the antiretroviral effects of the combination of two anti-human immunodeficiency virus (HIV) broadly neutralizing antibodies, 3BNC117 and 10-1074, administered intravenously in HIV-infected individuals. This study is intended to support the development of the combination of 3BNC117 and 10-1074 mAbs for use in the treatment of HIV-1 infection.
Primary Outcome
Adverse events include: signs, symptoms and laboratory abnormalities, in addition to local and systemic reactogenicity
Interventions
- DRUG Placebo
- DRUG 3BNC117
- DRUG 10-1074
- OTHER Analytical treatment interruption
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-06 |
| Est. Completion | 2018-08-15 |
| Phase | Phase 1 |
What the finished NCT02825797 record still lists
NCT02825797 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02825797 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02825797 about?
NCT02825797 is a clinical study titled "3BNC117 and 10-1074 in HIV-infected Individuals". This is a phase 1b clinical trial to evaluate the safety, pharmacokinetics and the antiretroviral effects of the combination of two anti-human immunodeficiency virus (HIV) broadly neutralizing antibodies, 3BNC117 and 10-1074, administered intravenously in HIV-infected individuals. This study is inte...
What is the current status of trial NCT02825797?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2016-06. Estimated completion is 2018-08-15.
What interventions are being tested in trial NCT02825797?
The interventions under investigation include: Placebo (DRUG), 3BNC117 (DRUG), 10-1074 (DRUG), Analytical treatment interruption (OTHER).
Who is sponsoring clinical trial NCT02825797?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02825797's enrollment target sits among peer trials
34 1273rd of 2000 higher than 721 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia